Navigation Links
Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
Date:1/9/2009

CHICAGO and PHOENIX, Jan. 9 /PRNewswire/ -- Houlihan Smith & Co., Inc. acted as the exclusive advisor in arranging a non-control equity investment into Sottera, Inc. d/b/a NJOY, as announced by Charles Botchway, Group Managing Director and Vice Chairman of Houlihan Smith & Company, Inc. The transaction was led by Houlihan Smith Managing Director Reginald McGaugh. Terms were not disclosed.

"We appreciate the process management and financial advisory services provided by Reginald McGaugh and his team at Houlihan Smith & Company, Inc. related to this equity investment," said Jack Leadbeater, CEO of Sottera. "We look forward to continuing our capital-raising process with Mr. McGaugh and his team as we continue our international growth."

"This investment represents a significant opportunity for NJOY to achieve growth initiatives related to its revolutionary product," said McGaugh, who worked directly with NJOY to establish the equity investment. "The facility will be used to support the continued growth of NJOY based on recently signed distribution agreements in North America, South America, and Asia."

Based in Scottsdale, Arizona, Sottera has filed for patents to manufacture and distribute groundbreaking products and technology represented by the trademarked brand NJOY (http://www.njoy.com). The name Sottera is derived from Soteria, the Greek god of preservation, redemption and salvation. These three words are the essence of the NJOY brand and products, which give tobacco users the opportunity to continue smoking with greater freedom, lower cost and more social acceptance. NJOY is currently being sold in all 50 states and in more than 25 foreign countries. NJOY is available online at http://www.njoy.com for shipment around the globe, and is also available on affiliated websites and a
'/>"/>

SOURCE Houlihan Smith & Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
2. GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.
3. AUDIO from Medialink and GlaxoSmithKline: FDA Approves Boostrix for Adults
4. GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
5. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
6. GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.
7. US District Court Enters Final Judgment in Favor of Smith & Nephew; Permanent Injunction Prohibits Arthrex Inc. From Selling Infringing Medical Devices
8. SpineSmith Partners Collaborates with University of Texas Biomedical Engineering Students to Develop Innovative Products
9. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
10. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
11. District Court Sides with Smith & Nephew; Rules that It will Issue Injunction that will Prohibit Arthrex Inc. from Selling Infringing Medical Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Savoury Systems International (SSI), a leader in the ... USA Sales Broker. Braddy’s new role will allow SSI ... , In 2004 Braddy founded Southeastern Food ... processors and industrial manufacturers. Braddy has worked for ... has over 25 years of sales management experience. ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Smarter Security, ... security solutions, today announced that Genzyme, a Sanofi company ... of Door Detective® CL for a multi-use facility in ... in four other Genzyme buildings, this latest order underscores ... the tailgate detection device improving doorway access ...
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... Norristown, PA (PRWEB) May 21, 2013 ... company, today announced that Dr. Charles Signorino, the Company’s ... on April 1, 2013 after 32 years of service. ... Adolfo Gomez, Emerson’s current President, has been named as ... recognized luminary in the pharmaceutical industry, having made a ...
Breaking Biology Technology:Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3
... ... cGMP manufacturer, announced that the company is in the initial phases of a multi-year ... Ingredient (API) manufacturing facility located in Riverview, Michigan. Expansions will include a new reactor ... ...
... , CRANBURY, N.J., Sept. 30 Amicus Therapeutics (Nasdaq: ... 1 study of AT2220 (1-deoxynojirimycin HCl), its investigational drug in ... objective of this study is to evaluate the pharmacokinetics of ... U.S. Food and Drug Administration (FDA) has agreed to Amicus, ...
... Despite a number of key issues such as ... and feed uses, global use of biofuels is excepted to ... new global analysis released today by Hart,s Global Biofuels Center. ... of total biofuels use of more than 35%. Brazil will ...
Cached Biology Technology:Ash Stevens Plans $6 Million Facility Expansion to Bolster CMC Capabilities 2Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 2Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 3Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 4Global Biofuels Growth to Double by 2015 2Global Biofuels Growth to Double by 2015 3Global Biofuels Growth to Double by 2015 4
(Date:5/17/2013)... Scientists investigating the interaction of a group of proteins ... damage have identified a new target that could increase ... the University,s School of Biochemistry and published in the ... Reviews, could eventually lead to new therapies for stroke ... earlier work by the team which identified a protein, ...
(Date:5/17/2013)... MD The Federation of American Societies for Experimental ... National Institutes of Health (NIH) funding trends highlighting the ... support critical research. The FASEB analysis follows a May ... Collins, MD, PhD, who testified that the $1.6 billion ... sequestration is "having a substantial impact on the scientific ...
(Date:5/16/2013)... MD FASEB MARC (Maximizing Access to Research ... for The Society for Developmental Biology (SDB) 72nd ... 2013. These awards are meant to promote the ... groups into the mainstream of the basic science ... scientists at the SDB 2013 Annual Meeting. , ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2
... pleased to announce an exclusive commercial license agreement ... plants and with important implications for crop improvement. ... is licensing the technology to Dow AgroSciences. Dow ... Chemical Company (NYSE: DOW), entered into an exclusive ...
... evolve for months after a traumatic brain injury (TBI), ... trauma, new research led by the University of Melbourne, ... Victorian Neurotrauma Initiative is published in the latest issue ... Around 400,000 Australians have a disability related to ...
... help from their female friends are far more successful as ... new study. , Previous research into reproductive success in animal ... benefits of inherited genetic characteristics, while others show the benefits ... uncle or other unrelated helpers. , The new ...
Cached Biology News:Dow Agrosciences licenses exclusive novel crop enhancement technology 2Study provides treatment hope for long term effects of brain trauma 2Successful mothers get help from their friends: Dolphin study 2
Rat Aortic Smooth Muscle Cells (RAOSMC) (>500,000 cells)...
Rat Aortic Endothelial Cells (RAOEC) (>500,000 cells)...
... The Brownlee Precision Model 440 incorporates ... circuitry in a friendly easy-to-use instrument. Each ... amplifier, an 8-pole Bessel lowpass filter, a ... output offset controls. A control knob sets ...
... fully licensed, high throughput, water bath thermal cycler ... 24 microplates. This equates to 9,216 reactions per ... robotic arm rapidly transfers a basket of plates ... times that are considerably faster than those of ...
Biology Products: